

# ARKANSAS MEDICAID PROVIDER QUARTERLY NEWSLETTER

MagellanRx  
MANAGEMENT<sup>SM</sup>



THE NUMBERS LISTED  
BELOW ARE FOR  
FEE-FOR-SERVICE (FFS)  
SUPPORT

**Magellan Pharmacy  
Support Center  
(Pharmacy, Member, and  
Prior Authorization)**  
1-800-424-7895  
Monday – Friday  
8:00 a.m. – 5:00 p.m.,  
Central Time (CT)  
excluding State holidays

**Clinical PA Fax**  
1-800-424-7976  
24 Hours A Day,  
7 Days a Week

**Magellan Clinical PA Fax  
(PDL) 1-800-424-5739**  
24 Hours A Day,  
7 Days a Week

**Division of Medical  
Services Pharmacy Unit**  
P.O. Box 1437, Slot S-415  
Little Rock, AR 72203  
Fax: 501-683-4124 OR  
800-424-5851  
Phone: 501-683-4120  
Monday – Friday  
8:00 a.m. – 4:30 p.m.,  
Central Time (CT)  
excluding State holidays

## JANUARY 2022

### UPCOMING LEGISLATIVE IMPLEMENTATIONS

#### ACT 406 (HB 1134)

- This Act gives pharmacists via scope of practice the right to prescribe, administer, deliver, distribute, or dispense vaccines, immunizations, and medications to treat adverse actions to those administered vaccines.
- The estimated implementation will take place in May 2022.

#### ACT 758 (HB1781)

- The Act will remove the 3 prescription slot limits for adults and increase to a 6-prescription limit per month, and certain maintenance drugs will not count against the limit of 6. Extension of benefits is no longer needed.
- The implementation date will be January 1, 2022

### DUR BOARD UPDATE

The following will be presented during the January 19, 2022 Drug Utilization Review Board meeting.

- PROPOSED CHANGES TO EXISTING CRITERIA:
  - Palforzia® re-review
  - Quetiapine POS edit
- PROPOSED NEW CLINICAL POINT-OF-SALE CRITERIA:
  - Rescue seizure medications
- MANUAL REVIEW PROPOSED CRITERIA:
  - Kerendia®
  - Tavneos™
  - Exkivity™
  - Opzelura™
  - Livmarli™
  - Scemblix®
  - Vuity™
  - Voxzogo™
  - Carbaglu®

See the Arkansas Magellan Website for additional information:

<https://arkansas.magellanrx.com/>

### PREFERRED DRUG LIST

Upcoming Drug Review Committee (DRC) classes to review on February 9, 2022

- Anticonvulsants
- Immunoglobulins

See the Arkansas Magellan Website for additional information:

[https://arkansas.magellanrx.com/client/docs/other/ARRx\\_DRC\\_meeting\\_schedule.pdf](https://arkansas.magellanrx.com/client/docs/other/ARRx_DRC_meeting_schedule.pdf)

# ARKANSAS MEDICAID PROVIDER QUARTERLY NEWSLETTER

MagellanRx  
MANAGEMENT<sup>SM</sup>



THE NUMBERS LISTED  
BELOW ARE FOR  
FEE-FOR-SERVICE (FFS)  
SUPPORT

**Magellan Pharmacy  
Support Center  
(Pharmacy, Member, and  
Prior Authorization)**  
1-800-424-7895  
Monday – Friday  
8:00 a.m. – 5:00 p.m.,  
Central Time (CT)  
excluding State holidays

**Clinical PA Fax**  
1-800-424-7976  
24 Hours A Day,  
7 Days a Week

**Magellan Clinical PA Fax  
(PDL) 1-800-424-5739**  
24 Hours A Day,  
7 Days a Week

**Division of Medical  
Services Pharmacy Unit**  
P.O. Box 1437, Slot S-415  
Little Rock, AR 72203  
Fax: 501-683-4124 OR  
800-424-5851  
Phone: 501-683-4120  
Monday – Friday  
8:00 a.m. – 4:30 p.m.,  
Central Time (CT)  
excluding State holidays

## INCREASED OFF-LABEL USE OF QUETIAPINE

### CURRENT INDICATIONS:

- Acute treatment of schizophrenia in patients  $\geq 13$  years of age
- Bipolar I disorder
  - Acute treatment of manic episodes in patients  $\geq 10$  years of age
    - Monotherapy
    - Adjunct to lithium or divalproex
  - Monotherapy for acute treatment of depressive episodes in adults
  - Maintenance treatment as adjunct to lithium or divalproex in adults
- Bipolar II disorder—Monotherapy for acute treatment of depressive episodes in adults

Antipsychotics, especially at lower doses, have surged in popularity for treating many psychiatric and behavioral disturbances, including anxiety, insomnia, and agitation. Approximately 40-75% of antipsychotic usage is for off-label diagnoses. Potential side effects should be considered before prescribing antipsychotic medications for off-label uses.

Atypical antipsychotics may cause weight gain, type II diabetes, sedation, hypertension, hyperlipidemia, and extrapyramidal side effects. Quetiapine and olanzapine along with clozapine are considered to exhibit the highest risk for cardiometabolic symptoms.

Per the quetiapine package insert, caution should be taken in patients with known cardiovascular disease or an increased risk of QT prolongation. Evidence suggests that prolonged, off-label exposure to quetiapine (even low doses) is associated with an increased risk for cardiometabolic mortality due to cardiomyopathy and myocarditis. Before prescribing, a thorough risk-benefit analysis should be performed, with screening and follow-up being well utilized regardless of prescribed dose or length of treatment.

- <https://pubmed.ncbi.nlm.nih.gov/23951594/>
- <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0584dda8-bc3c-48fe-1a90-79608f78e8a0>
- <https://www.sciencedirect.com/science/article/pii/S0022395621006725>

# ARKANSAS MEDICAID PROVIDER QUARTERLY NEWSLETTER



THE NUMBERS LISTED BELOW ARE FOR FEE-FOR-SERVICE (FFS) SUPPORT

**Magellan Pharmacy Support Center (Pharmacy, Member, and Prior Authorization)**  
 1-800-424-7895  
 Monday – Friday  
 8:00 a.m. – 5:00 p.m.,  
 Central Time (CT)  
 excluding State holidays

**Clinical PA Fax**  
 1-800-424-7976  
 24 Hours A Day,  
 7 Days a Week

**Magellan Clinical PA Fax (PDL)** 1-800-424-5739  
 24 Hours A Day,  
 7 Days a Week

**Division of Medical Services Pharmacy Unit**  
 P.O. Box 1437, Slot S-415  
 Little Rock, AR 72203  
 Fax: 501-683-4124 OR  
 800-424-5851  
 Phone: 501-683-4120  
 Monday – Friday  
 8:00 a.m. – 4:30 p.m.,  
 Central Time (CT)  
 excluding State holidays

## COVID-19 VACCINATION RATE


Arkansas Medicaid client COVID-19 vaccination rates are found in the chart below as of January 6, 2022.

| COVID-19 Vaccine Administration     |                             | Total Doses | Total Recipients | Total Paid (FFS & ENC) |
|-------------------------------------|-----------------------------|-------------|------------------|------------------------|
| Billing Provider Type & Desc<br>All | Claim Encounter Code<br>All | 124,165     | 74,261           | \$6,000,019            |

Last Update: 1/3/2022 10:09:57 AM


What is the distribution of doses by labeler?

Select labeler to filter dashboard. Hover to see % by first and second dose.



How many days are between first dose and second dose?


Labeler reflected as appears for second dose.



■ Pfizer 1st    ■ Pfizer 2nd    ■ Pfizer 3rd    
 ■ Moderna 1st    ■ Moderna 2nd    ■ Moderna 3rd    
 ■ Janssen

How many doses are given each week?

Week is reflected by service date.



# ARKANSAS MEDICAID PROVIDER QUARTERLY NEWSLETTER



THE NUMBERS LISTED  
BELOW ARE FOR  
FEE-FOR-SERVICE (FFS)  
SUPPORT

**Magellan Pharmacy  
Support Center  
(Pharmacy, Member, and  
Prior Authorization)**  
1-800-424-7895  
Monday – Friday  
8:00 a.m. – 5:00 p.m.,  
Central Time (CT)  
excluding State holidays

**Clinical PA Fax**  
1-800-424-7976  
24 Hours A Day,  
7 Days a Week

**Magellan Clinical PA Fax  
(PDL) 1-800-424-5739**  
24 Hours A Day,  
7 Days a Week

**Division of Medical  
Services Pharmacy Unit**  
P.O. Box 1437, Slot S-415  
Little Rock, AR 72203  
Fax: 501-683-4124 OR  
800-424-5851  
Phone: 501-683-4120  
Monday – Friday  
8:00 a.m. – 4:30 p.m.,  
Central Time (CT)  
excluding State holidays

## PLAN PREFERS BRAND

After a brand name drug's patent has expired there may be a company producing a generic drug that meets the FDA's criteria for the "181-day generic drug exclusivity", which means it is protected from competition from other generic versions of the same drug product for approximately 181 days. After the expiration of the 181-day exclusivity period, other generic companies may be poised to enter the market and as more generic drugs are available, the price begins to fall.

The state Medicaid pharmacy program staff will monitor these high cost brand-name drugs and check the Federal rebate file to determine the most economical choice for the state, either:

- The brand name drug due to a higher Federal rebate and lower final net cost to the state; OR
- The generic drug that likely has the 181-day generic exclusivity without other generic competition

When there is sufficient supply of the generic drugs and the price of the generics has fallen to less than the final net cost of the brand name drug, the generic may be the most cost-effective choice for the state. At that time, the Medicaid staff may place a State Maximum Allowable Cost (MAC) on both the brand and the generic drugs for that specific drug/strength/dosage form. Until that occurs, Arkansas Medicaid will require the Brand drug to continue to be dispensed by pharmacies. Please note clinical criteria and claim edits will still apply.

Pharmacies will receive a 30-day notice prior to Arkansas Medicaid applying a MAC on the brand and generic drugs related to State Supported Brand Medications.

Effective February 15, 2022, the following brand name products will be removed from the State supported brand list. Pharmacies should begin processing claims with generics on that date.

- Atripla®
- Truvada®

Current State Supported Brand List can be found with the following link:  
[https://arkansas.magellanrx.com/client/docs/rxinfo/State\\_Supported\\_Brand\\_Meds.pdf](https://arkansas.magellanrx.com/client/docs/rxinfo/State_Supported_Brand_Meds.pdf)

# ARKANSAS MEDICAID PROVIDER QUARTERLY NEWSLETTER

MagellanRx  
MANAGEMENT<sup>SM</sup>



## THE NUMBERS LISTED BELOW ARE FOR FEE-FOR-SERVICE (FFS) SUPPORT

**Magellan Pharmacy  
Support Center  
(Pharmacy, Member, and  
Prior Authorization)**  
1-800-424-7895  
Monday – Friday  
8:00 a.m. – 5:00 p.m.,  
Central Time (CT)  
excluding State holidays

**Clinical PA Fax**  
1-800-424-7976  
24 Hours A Day,  
7 Days a Week

**Magellan Clinical PA Fax  
(PDL) 1-800-424-5739**  
24 Hours A Day,  
7 Days a Week

**Division of Medical  
Services Pharmacy Unit**  
P.O. Box 1437, Slot S-415  
Little Rock, AR 72203  
Fax: 501-683-4124 OR  
800-424-5851  
Phone: 501-683-4120  
Monday – Friday  
8:00 a.m. – 4:30 p.m.,  
Central Time (CT)  
excluding State holidays

## USEFUL LINKS

### DHS webpage

- <https://humanservices.arkansas.gov/divisions-shared-services/medical-services/helpful-information-for-providers/>

### DHS provider manuals

- <https://humanservices.arkansas.gov/divisions-shared-services/medical-services/helpful-information-for-providers/manuals/>

### Opioid guidance

- <https://arkansas.magellanrx.com/client/documents>
- <http://www.cdc.gov/drugoverdose/prescribing/guideline.html>
- <https://www.samhsa.gov/medication-assisted-treatment>
- <https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf>
- [The Dangers Of Mixing Benzodiazepines With Opiates - Opioid Treatment](#)
- <https://www.cdc.gov/drugoverdose/index.html>
- <https://www.rehabs.com/blog/the-polypharmacy-overdose-a-killer-trend/>
- <https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline>

## DUR BOARD MEETING DATES

- [January 19, 2022](#)
- [April 20, 2022](#)
- [July 20, 2022](#)
- [October 19, 2022](#)

# ARKANSAS MEDICAID PROVIDER QUARTERLY NEWSLETTER

MagellanRx  
MANAGEMENT<sup>SM</sup>

